Senior Management Appointment
Belluscura plc
("Belluscura" or the "Company" or "Group")
Senior Management Appointment
LONDON, U.K. AND PLANO, TX, U.S. (21 April 2022) . Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Brian Brown has joined the Company as Vice President of Engineering.
Brian has over 25 years of experience in commercializing break-through new products in hardware, software, and service delivery industries. In his career, Brian built a start-up firm into a world leading supplier of diagnostic imaging medical devices holding the titles of President and Chief Innovation Officer. In addition to degrees in electrical engineering, he is a registered professional engineer and is the author of 17 US patents.
Robert Rauker, Chief Executive Officer, Belluscura plc, commented: "We look forward to leveraging Brian's background in new product commercialization. His knowledge in building a start-up medical device firm will add to our experienced management team. We're excited to have Brian on board."
Brian Brown commented: "It's exciting to be part of a very talented Belluscura team. I look forward to helping Belluscura launch its breakthrough new technologies and change the face of patient care."
For further information please contact:
|
|
|
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 3 hours ago Rathbones Group
- 3 hours ago Quartix Technologies
- 3 hours ago C&C Group (CDI)
- 3 hours ago Aquila Energy Efficiency Trust (EUR)
- 4 hours ago Cranswick